Skip to main content

BRIEF RESEARCH REPORT article

Front. Transplant.
Sec. Abdominal Transplantation
Volume 3 - 2024 | doi: 10.3389/frtra.2024.1483943

Diagnosis and Management of De Novo Inflammatory Bowel Disease After Solid Organ Transplantation in the Era of Biologic Therapy: A Case Series

Provisionally accepted
Willie Johnson Willie Johnson *Byron P Vaughn Byron P Vaughn Nicholas Lim Nicholas Lim
  • University of Minnesota Health Sciences, University of Minnesota Medical Center, Minneapolis, United States

The final, formatted version of the article will be published soon.

    The clinical characteristics of de novo inflammatory bowel disease (dnIBD) diagnosed after solid organ transplant (SOT) are not well-described, particularly since the advent of biologic therapy for treatment of IBD.We conducted a single-center, retrospective review of SOT recipients between 2010 and 2022 at the University of Minnesota Medical Center who were diagnosed with IBD after transplant.Of 89 patients at our center with IBD and a history of SOT, five (5.6%) patients were diagnosed with IBD post-transplant (three liver, one kidney, and one simultaneous liver and kidney): three patients were female and four were Caucasian. Mean age at transplant and IBD diagnosis were 46.7 and 49.4 years respectively. Indication for transplant were alcohol-related cirrhosis (n=2), idiopathic fulminant hepatic failure (n=1), metabolic dysfunction-associated steatotic liver disease (n=1), and IgA nephropathy (n=1). Four patients were diagnosed with ulcerative colitis (UC) and one with Crohn's disease (CD). Three patients (all with UC) required escalation to a biologic therapy. Four patients were in clinical remission from IBD at last follow-up, one patient required IBD surgery, while there was no rejection and no deaths following IBD diagnosis.dnIBD post-SOT is uncommon, while newer IBD therapies may be safe and effective. Further study is required to better understand the natural history and IBD outcomes of this population relative to non-SOT patients.

    Keywords: solid organ transplant, Crohn's disease, ulcerative colitis, Immunosuppression, inflammatory bowel disease

    Received: 20 Aug 2024; Accepted: 23 Dec 2024.

    Copyright: © 2024 Johnson, Vaughn and Lim. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Willie Johnson, University of Minnesota Health Sciences, University of Minnesota Medical Center, Minneapolis, United States

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.